ReviewCancers2021
Hypoxia in Lung Cancer Management: A Translational Approach.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and carbon ions irradiation.Molecular and cellular biochemistry · 2026Article
- Hydrogen sulfide at the intersection of hypoxia and oxidative stress: implications for lung cancer progression and treatment - a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Effect of Reoxygenation on Radioresistance of Chronically Hypoxic A549 Non-Small Cell Lung Cancer (NSCLC) Cells Following X-Ray and Carbon Ion Exposure.International journal of molecular sciences · 2025Article
- Advanced strategies to overcome multidrug resistance in cancer therapy: progress in P-glycoprotein inhibitors, drug delivery, and personalized medicine.Investigational new drugs · 2025Review
- Review
- Hypoxic Gene Expression Signature as a Predictor of Recurrence and Mortality in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.JCO precision oncology · 2025Article
- Modulation of the Antitumor Response to Metformin, Caffeine, and Sodium Dichloroacetate by the Hypoxic Microenvironment in Lung Cancer Cells.International journal of molecular sciences · 2025Article
- Identification of IGF2BPs-related mRNA signature for predicting the overall survival of lung adenocarcinoma.Scientific reports · 2025Article
- A Pilot Study on Qualitative Metabolomics to Characterize Lewis Lung Carcinoma in Mice.Life (Basel, Switzerland) · 2025Article
- Development of an AI model for predicting hypoxia status and prognosis in non-small cell lung cancer using multi-modal data.Translational lung cancer research · 2024Article
- miR-127/3p Inhibits Cell Migration in Lung Adenocarcinoma Under Hypoxic and Normal Oxygen Conditions.microPublication biology · 2024Article
- Hypoxia A Typical Target in Human Lung Cancer Therapy.Current protein & peptide science · 2024Review
- HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies.Life (Basel, Switzerland) · 2023Review
- Hypoxia-induced activation of NDR2 underlies brain metastases from Non-Small Cell Lung Cancer.Cell death & disease · 2023Article
- Article
- Construction of subtype classifiers and validation of a prognostic risk model based on hypoxia-associated lncRNAs for lung adenocarcinoma.Journal of thoracic disease · 2023Article
- Review
- A deformability-based biochip for precise label-free stratification of metastatic subtypes using deep learning.Microsystems & nanoengineering · 2023Article
- Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.Frontiers in immunology · 2023Review
- Recapitulating Tumor Hypoxia in a Cleanroom-Free, Liquid-Pinning-Based Microfluidic Tumor Model.ACS biomaterials science & engineering · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Lung cancer represents the first cause of death by cancer worldwide and remains a challenging public health issue. Hypoxia, as a relevant biomarker, has raised high expectations for clinical practice. Here, we review clinical and pathological features related to hypoxic lung tumours. Secondly, we expound on the main current techniques to evaluate hypoxic status in NSCLC focusing on positive emission tomography. We present existing alternative experimental approaches such as the examination of circulating markers and highlight the interest in non-invasive markers. Finally, we evaluate the relevance of investigating hypoxia in lung cancer management as a companion biomarker at various lung cancer stages. Hypoxia could support the identification of patients with higher risks of NSCLC. Moreover, the presence of hypoxia in treated tumours could help clinicians predict a worse prognosis for patients with resected NSCLC and may help identify patients who would benefit potentially from adjuvant therapies. Globally, the large quantity of translational data incites experimental and clinical studies to implement the characterisation of hypoxia in clinical NSCLC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.